We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Micro Ribonucleic Nucleic Acid Panel Assays Launched

By LabMedica International staff writers
Posted on 28 Sep 2015
A novel approach has been developed by combinations of micro ribonucleic nucleic acid (miRNA) specific reverse transcriptase and hemi-nested real-time polymerase chain reaction (PCR) primers that have been designed to maximize miRNA detection sensitivity and specificity.

The miRNA Panel Assays provide scientists with a convenient way to quickly analyze miRNAs that suggest a correlation with the dysregulations in various cancers, in maintenance, differentiation and reprogramming of stem cells and to look at circulating miRNAs that are regarded as a promising new class of biomarkers.

The real-time PCR assays use SensiSMART with SYBR Green (Bioline USA Inc.; Taunton, MA, USA) to enable detection of extremely low levels of miRNA with high specificity, allowing the discrimination between closely related miRNA sequences. More...
This highly reproducible, sensitive platform has been validated independently by molecular diagnostic and pharmaceutical laboratories and showed superior performance to existing commercial assays.

The Bioline EPIK miRNA Panel Assays were developed for miRNA profiling of cancer samples, biofluids, and stem cells. The EPIK miRNA Panel Assays are the result of collaboration with MiRXES (Singapore). Marco Calzavara, president of Bioline, said, “The release of the EPIK miRNA Panel Assays follows the release of the ISOLATE II miRNA, Biofluids RNA, RNA/DNA/Protein and FFPE RNA/DNA Kits earlier this year and shows the continued commitment of Bioline to produce high quality miRNA kits to help researchers with miRNA expression profiling and quantification and in biomarker discovery.”

Richard L. Eberly, president of Meridian Life Science, Inc. (Cincinnati, OH, USA), the parent company, stated, "We are excited about the release of the EPIK miRNA Panel Assays and the enhanced performance they provide for our important life science customers in the molecular diagnostic and pharmaceutical laboratories and biotechnology companies. We remain committed to the continued expansion of the rapidly growing portfolio of highly specialized molecular biology products from Bioline.”

Related Links:

Bioline USA Inc.
MiRXES 
Meridian Life Science, Inc.



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.